RegenETP, Inc.

BST:NJT Stock Report

Market Cap: €162.8k

RegenETP Management

Management criteria checks 4/4

RegenETP's CEO is Richard Hague, appointed in Apr 2020, has a tenure of 3.67 years. total yearly compensation is $479.81K, comprised of 93.5% salary and 6.5% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth €1.01K. The average tenure of the management team and the board of directors is 4.5 years and 6.5 years respectively.

Key information

Richard Hague

Chief executive officer

US$479.8k

Total compensation

CEO salary percentage93.5%
CEO tenure3.7yrs
CEO ownership0.6%
Management average tenure4.5yrs
Board average tenure6.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Richard Hague's remuneration changed compared to RegenETP's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$8m

Dec 31 2022US$480kUS$449k

-US$8m

Sep 30 2022n/an/a

-US$16m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$1mUS$359k

-US$30m

Sep 30 2021n/an/a

-US$32m

Jun 30 2021n/an/a

-US$38m

Mar 31 2021n/an/a

-US$47m

Dec 31 2020US$996kUS$358k

-US$43m

Sep 30 2020n/an/a

-US$54m

Jun 30 2020n/an/a

-US$70m

Mar 31 2020n/an/a

-US$80m

Dec 31 2019US$2mUS$273k

-US$92m

Compensation vs Market: Richard's total compensation ($USD479.81K) is about average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Richard's compensation has been consistent with company performance over the past year.

CEO

Richard Hague (63 yo)

3.7yrs

Tenure

US$479,808

Compensation

Mr. Richard Hague is Director of Remedium Bio, Inc since 2022. He serves as President at PolarityTE, Inc. since August 2019 and its Chief Executive Officer since August 2021 and also served as its Chief Op...

Leadership Team

NamePositionTenureCompensationOwnership
Richard Hague
President3.7yrsUS$479.81k0.62%
€ 1.0k
Nikolai Sopko
Chief Scientific Officer and VP of R&D5.4yrsno datano data
Rich Haerle
Vice President of Investor Relations & Strategy5.6yrsno datano data
Mark Lehman
Chief Legal Officerno datano datano data
Angela Ziegler
Vice President of Marketing & Public Relationsno datano datano data
Alain Adam
Vice President of Sales5.4yrsno datano data
Jon Anthony Burrows
Senior VP of Corporate Development & President of Contract Servicesno datano datano data
Ryan Mathis
Chief Medical Officer2.3yrsno datano data
Kolby Day
Senior Vice President of Manufacturing Operations1.1yrsno datano data

4.5yrs

Average Tenure

Experienced Management: NJT's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Richard Hague
Presidentless than a yearUS$479.81k0.62%
€ 1.0k
Michael Callahan
Member of Clinical Advisory boardno datano datano data
Stephen Milner
Member of Clinical Advisory Board7yrsno datano data
Michael Grant
Member of Clinical Advisory Board7yrsno datano data
Anand Kumar
Member of Clinical Advisory Board7yrsno datano data
Anthony Tufaro
Member of Clinical Advisory Boardno datano datano data
Trinity Bivalacqua
Member of Clinical Advisory Boardno datano datano data
Shannath Merbs
Member of Clinical Advisory Boardno datano datano data
Ryan Katz
Member of Clinical Advisory Boardno datano datano data
Martin Robson
Member of Clinical Advisory Board6.5yrsno datano data
William Hickerson
Member of Clinical Advisory Board6.5yrsno datano data
Jeffrey Shupp
Member of Clinical Advisory Board6.5yrsno datano data

6.5yrs

Average Tenure

Experienced Board: NJT's board of directors are considered experienced (6.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/04 18:47
End of Day Share Price 2023/09/06 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RegenETP, Inc. is covered by 11 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffB. Riley Wealth
Kristen KluskaCantor Fitzgerald & Co.
Joshua SchimmerEvercore ISI